Tag Archives: Shire

Wed, Aug 5 2009

Shire’s Adderall Sales Plunge; Shares Gain on Vyvanse Prospects

Also tagged: , , , , , , , , , ,

Aug. 5 (Bloomberg) — Shire Plc’s second-quarter revenue sank 19 percent as generic competition hurt sales of its Adderall hyperactivity pill. The shares gained the most since mid-April on prospects... 

No Comments | Read More »
Wed, Aug 5 2009

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

Also tagged: , , , , , , , , , , ,

DUBLIN, August 5 /PRNewswire-FirstCall/ — – 2009 Guidance Framework Reaffirmed Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the... 

No Comments | Read More »
Wed, Aug 5 2009

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

Also tagged: , , , , , , ,

LONDON, August 5 /PRNewswire/ — – 2009 Guidance Framework Reaffirmed Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months... 

No Comments | Read More »
Wed, Aug 5 2009

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

Also tagged: ,

- AKPC_IDS += "3449,"; ...

No Comments | Read More »
Sun, Aug 2 2009

Study Demonstrated Once-Daily Vyvanse(R) CII Provided Significant Improvement Of ADHD Symptoms For Children At 13 …

Also tagged: , , , , , , , , , , , , , , ,

Shire plc announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly... 

No Comments | Read More »
Tue, Jul 28 2009

FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in …

Also tagged: , , , , , , , , , , , , ,

PHILADELPHIA, July 28 /PRNewswire-FirstCall/ — Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Complete Response letter today... 

No Comments | Read More »